Galera Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

Rhea-AI Summary

Galera Therapeutics (Nasdaq: GRTX) announced that its CEO, Mel Sorensen, will present virtually at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 22, 2020, at 1:40 p.m. EDT. A live webcast can be accessed via Galera's Investors page, with an archived version available for 30 days post-event. Galera focuses on developing novel therapeutics to enhance cancer radiotherapy, with its flagship product, avasopasem manganese (GC4419), currently undergoing multiple clinical trials.

MALVERN, Pa., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that Mel Sorensen, M.D., President and Chief Executive Officer, will virtually present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on Tuesday, September 22, 2020, at 1:40 p.m. EDT.

A live webcast of the presentation will be accessible from the Investors page of Galera’s website, investors.galeratx.com. An archived version of the webcast will be available in the News & Events section of the Investors page of Galera’s website for 30 days following the event.

About Galera Therapeutics

Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer. Galera’s lead product candidate is avasopasem manganese (GC4419), a highly selective small molecule superoxide dismutase (SOD) mimetic initially being developed for the reduction of radiation-induced severe oral mucositis (SOM). Avasopasem is being studied in the Phase 3 ROMAN trial for its ability to reduce the incidence and severity of SOM induced by radiotherapy in patients with locally advanced head and neck cancer (HNC), its lead indication. It is also being studied in a Phase 2a multi-center trial in Europe assessing the safety of avasopasem in patients with HNC undergoing standard-of-care radiotherapy, a Phase 2a trial for its ability to reduce the incidence of esophagitis induced by radiotherapy in patients with lung cancer and completed enrollment in a pilot Phase 1/2 trial in combination with stereotactic body radiation therapy (SBRT) in patients with locally advanced pancreatic cancer. The FDA granted Fast Track and Breakthrough Therapy designations to avasopasem for the reduction of SOM induced by radiotherapy. Galera is headquartered in Malvern, PA. For more information, please visit www.galeratx.com.

Investor Contacts:
Christopher Degnan
Galera Therapeutics, Inc.
610-725-1500
cdegnan@galeratx.com

Jennifer Porcelli
Solebury Trout
646-378-2962
jporcelli@soleburytrout.com

Media Contact:
Heather Anderson
6 Degrees
919-827-5539
handerson@6degreespr.com

FAQ

What will Galera Therapeutics present at the Oppenheimer Summit on September 22, 2020?

Galera Therapeutics will present updates regarding its therapeutic innovations and pipeline, particularly focusing on avasopasem manganese.

When is the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit?

The summit is scheduled for September 22, 2020.

How can I access the live webcast of Galera Therapeutics' presentation?

The live webcast can be accessed from the Investors page on Galera Therapeutics' website.

What is avasopasem manganese and its significance?

Avasopasem manganese (GC4419) is designed to reduce radiation-induced severe oral mucositis in cancer patients.

What are the current studies involving avasopasem manganese?

Avasopasem is involved in Phase 3 and Phase 2a trials for reducing mucositis and esophagitis in cancer patients.